Skip to main content

Table 3 Univariate analysis of clinicopathological data and A-FABP expression in relation to RFS and PFS of patients with NMIBC

From: Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

  HR RFS P HR PFS P
95% CI 95% CI
+ +
pTa
 Sex (F) 0.60 0.24 1.53 0.280 0.04 0.00 22.1 0.111
 Age (> 72) 1.21 0.65 2.28 0.547 1.16 0.38 3.54 0.800
 Histology (variants) 0.99 0.14 7.26 0.997 0.05 0.00 404,941.26 0.574
 Grade (for each change of category) 1.14 0.71 1.83 0.564 1.27 0.54 2.99 0.763
Cis (yes)     NA     NA
 A-FABP negativity 0.55 0.3 1.02 0.055 0.34 0.10 0.97 0.045
pT1
 Sex (F) 0.04 0.00 16.09 0.102 4.34 0.41 46.4 0.187
 Age (> 72) 2.04 0.84 5.00 0.110 0.75 0.12 4.6 0.756
 Histology (variants) 0.04 0.00 129.34 0.245 0.05 0.00 18,539,252.39 0.646
 Grade (for each change of category) 0.58 0.17 1.96 0.373 25.34 0.00 2,740,610.19 0.392
Cis (yes) 0.03 0.00 3.65 0.151 0.04 0.00 1840.31 0.350
 A-FABP negativity 1.22 0.51 2.91 0.648 0.39 0.04 3.48 0.380
pTa/pT1
 Sex (F) 0.43 0.17 1.09 0.074 0.38 0.05 2.86 0.347
 Age (> 72) 1.52 0.92 2.51 0.104 1.01 0.39 2.63 0.976
 Histology (variants) 0.48 0.07 3.47 0.468 0.05 0.00 11,861.4 0.631
 Stage (pT1) 1.71 1.01 2.9 0.048 1.06 0.38 2.99 0.907
 Grade (for each change of category) 1.28 0.89 1.83 0.183 1.27 0.65 2.48 0.487
Cis (yes) 0.05 0.00 5.19 0.201 1.3 0.17 9.79 0.797
 A-FABP negativity 0.66 0.40 1.08 0.099 0.36 0.13 0.96 0.041
  1. *Abbreviations: NMIBC (pTa and pT1) Non-muscle invasive bladder cancer, CI Confidence interval, HR Hazard ratio, RFS Recurrence-free survival, PFS Progression-free survival
\